JOANNEUM RESEARCH HEALTH

Invitation for Partnership

Clinical Dermal Open Flow Microperfusion

THE INNOVATION COMPANY

Partnership Opportunity

We will provide a comprehensive technology transfer package, which includes:

- Transfer, training and certification of the dOFM™ technology and clinical protocols
- Exclusive purchasing/leasing of the clinical dOFM™ components and hardware
- Right-to-use of the dOFM™ trademark and patents for the associated services
- Re-certification and continue education program for the partner staff
- Technology support and optional consultancy service to facilitate trial execution
- Bespoke dOFM™ technical literature and publication to support marketing campaign

Financial Terms

We envision the financial agreement with the partners to include:

- Upfront, one-time payment to cover the initial training/certification and tech transfer
- Annual maintenance fee to re-certify staff and update technology/protocol in order to retain the right to use dOFM™ trademark/patents
- Project volume-based commission

The potential partners are expected to:

- Possess strong track record and significant experience (> 7 years) in conducting clinical trials to support dermatology drug development
- Possess all qualifications (e.g., license and certification) and suitable facility to conduct clinical dOFM™ trials in Europe, including established QM system for regulatory reporting and audit
- Provide dedicated staff to be trained and certified to conduct clinical dOFM™ trials
- Initiate and participate in relevant dOFM™ marketing campaign, including representations at conferences and trade shows



We are seeking a limited number of qualified partners, so please forward your letter of interest (LOI) by

December 31, 2022

For further inquiry and LOI submission, please contact: clinical.partner@joanneum.at

Background



Dermal Open Flow Microperfusion (**dOFM™**) is a proprietary continuous **skin tissue sampling technique** developed by JOANNEUM RESEARCH Forschungsgesellschaft mbH. It has been successfully applied in the **in-vitro** (using ex-vivo animal and human tissues), **preclinical in-vivo** (rat and pig models) and **clinical settings** to generate unique, time-resolved dermal PK/PD data to **support dermatology drug development**.

Specifically, clinical dOFM™ studies have been conducted to determine PK-PD correlations at or near the site of action to de-risk and endorse later-stage clinical trials and further development decision. For example, clinical dOFM™ PK/PD data have been used to support first line treatment approval of Secukinumab in several countries. Furthermore, we have been **collaborating with US FDA** since 2017 to show that the dOFM™ is the only proven clinical cutaneous pharmacokinetic approach to be able to establish bioequivalence for topical generics.

From such collaboration and our extensive clinical trial experience, we have developed a **unique set of expertise** and **standardized protocols** for conducting and interpreting clinical dOFM™ trials. Finally, JOANNEUM RESEARCH Forschungsgesellschaft mbH is the sole source of the CE-certified, clinical dOFM™ components and hardware, including the purpose-built precision push-pull pumps.

HEALTH

Institute for Biomedicine and Health Sciences

Neue Stiftingtalstrasse 2
8010 Graz
clinical.partner@joanneum.at

Frank Sinner, PhD
Vice President
JOANNEUM RESEARCH
HEALTH

Hsiao Wen-Kai, PhD
Business Developer
Biomedical Tissue Monitoring

www.joanneum.at/health/en

prmpbf22611